Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, PK, PD and immunogenicity of CM310 in children patients with moderate-to-severe atopic dermatitis.
- EligibilityCriteria: Inclusion Criteria:  Have the ability to understand the study and voluntarily sign a written informed consent form (ICF). With Atopic Dermatitis.  Exclusion Criteria:  Not enough washing-out period for previous therapies. Any major surgery planned during the research period. With intestinal parasitic infection within the 6 months before screening. With any circumstance that is not suitable to participate in this study. Major surgeries are planned during the study period. - HealthyVolunteers: No - Gender: All - MinimumAge: 12 Years - MaximumAge: 18 Years - StdAgeList: Child, Adult